{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T09:07:04Z","timestamp":1771146424706,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10585-019-09984-z","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:10:08Z","timestamp":1564744208000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-4078","authenticated-orcid":false,"given":"Federico","family":"Carbone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Vecchi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Bardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Ansaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Rijavec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Dal Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Biello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tagliamento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Alama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Coco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Dallegri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"issue":"1","key":"9984_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","volume":"19","author":"X Sun","year":"2019","unstructured":"Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X (2019) Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19(1):558. \n                    https:\/\/doi.org\/10.1186\/s12885-019-5701-6","journal-title":"BMC Cancer"},{"key":"9984_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/ITT.S125070","volume":"7","author":"S Raju","year":"2018","unstructured":"Raju S, Joseph R, Sehgal S (2018) Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7:63\u201375. \n                    https:\/\/doi.org\/10.2147\/ITT.S125070","journal-title":"Immunotargets Ther"},{"issue":"2","key":"9984_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"17","key":"9984_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"9984_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","volume":"112","author":"R Brody","year":"2017","unstructured":"Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J (2017) PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200\u2013215. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.005","journal-title":"Lung Cancer"},{"issue":"30","key":"9984_CR6","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","volume":"36","author":"S Devarakonda","year":"2018","unstructured":"Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S (2018) Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 36(30):2995\u20133006. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.78.1963","journal-title":"J Clin Oncol"},{"issue":"16","key":"9984_CR7","doi-asserted-by":"publisher","first-page":"11327","DOI":"10.1103\/PhysRevB.39.11327","volume":"39","author":"NE Glass","year":"1989","unstructured":"Glass NE, Rogovin D (1989) Transient electrodynamic response of thin-film superconductors to laser radiation. Phys Rev B Condens Matter 39(16):11327\u201311344","journal-title":"Phys Rev B Condens Matter"},{"issue":"10","key":"9984_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/1759-7714.12838","volume":"9","author":"T Takeda","year":"2018","unstructured":"Takeda T, Takeuchi M, Saitoh M, Takeda S (2018) Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. Thorac Cancer 9(10):1291\u20131299. \n                    https:\/\/doi.org\/10.1111\/1759-7714.12838","journal-title":"Thorac Cancer"},{"issue":"10","key":"9984_CR9","doi-asserted-by":"publisher","first-page":"e0197743","DOI":"10.1371\/journal.pone.0197743","volume":"13","author":"M Khunger","year":"2018","unstructured":"Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, Basu A, Pennell N, Stevenson JP, Elson P, Panchabhai TS, Velcheti V (2018) Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE 13(10):e0197743. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0197743","journal-title":"PLoS ONE"},{"issue":"8","key":"9984_CR10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","volume":"23","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P (2018) Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist 23(8):936\u2013942. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2017-0452","journal-title":"Oncologist"},{"key":"9984_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"issue":"8","key":"9984_CR12","first-page":"12765","volume":"8","author":"Y Liu","year":"2015","unstructured":"Liu Y, Gu X, Lin Q, Tian T, Shao L, Yuan C, Zhang B, Fan K (2015) Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. Int J Clin Exp Med 8(8):12765\u201312773","journal-title":"Int J Clin Exp Med"},{"key":"9984_CR13","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.2147\/OTT.S94082","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ (2015) The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. Onco Targets Ther 8:3513\u20133521. \n                    https:\/\/doi.org\/10.2147\/OTT.S94082","journal-title":"Onco Targets Ther"},{"issue":"6","key":"9984_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/eci.12446","volume":"45","author":"F Carbone","year":"2015","unstructured":"Carbone F, Vuilleumier N, Burger F, Roversi G, Tamborino C, Casetta I, Seraceni S, Trentini A, Padroni M, Dallegri F, Mach F, Fainardi E, Montecucco F (2015) Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. Eur J Clin Invest 45(6):579\u2013586. \n                    https:\/\/doi.org\/10.1111\/eci.12446","journal-title":"Eur J Clin Invest"},{"key":"9984_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijcard.2018.01.008","volume":"255","author":"F Carbone","year":"2018","unstructured":"Carbone F, Rigamonti F, Burger F, Roth A, Bertolotto M, Spinella G, Pane B, Palombo D, Pende A, Bonaventura A, Liberale L, Vecchie A, Dallegri F, Mach F, Montecucco F (2018) Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int J Cardiol 255:195\u2013199. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.008","journal-title":"Int J Cardiol"},{"key":"9984_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12975-018-0637-8","author":"F Carbone","year":"2018","unstructured":"Carbone F, Busto G, Padroni M, Bernardoni A, Colagrande S, Dallegri F, Montecucco F, Fainardi E (2018) Radiologic cerebral reperfusion at 24 h predicts good clinical outcome. Transl Stroke Res. \n                    https:\/\/doi.org\/10.1007\/s12975-018-0637-8","journal-title":"Transl Stroke Res"},{"issue":"5","key":"9984_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.numecd.2018.01.014","volume":"28","author":"F Carbone","year":"2018","unstructured":"Carbone F, Nulli Migliola E, Bonaventura A, Vecchie A, De Vuono S, Ricci MA, Vaudo G, Boni M, Dallegri F, Montecucco F, Lupattelli G (2018) High serum levels of C-reactive protein (CRP) predict beneficial decrease of visceral fat in obese females after sleeve gastrectomy. Nutr Metab Cardiovasc Dis 28(5):494\u2013500. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2018.01.014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"9984_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijrobp.2010.06.011","volume":"81","author":"C Dehing-Oberije","year":"2011","unstructured":"Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P (2011) Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 81(2):360\u2013368. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"9984_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-018-4193-0","volume":"18","author":"MJ Fidler","year":"2018","unstructured":"Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA (2018) The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer 18(1):310. \n                    https:\/\/doi.org\/10.1186\/s12885-018-4193-0","journal-title":"BMC Cancer"},{"issue":"2","key":"9984_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2009.02.004","volume":"66","author":"T Gu","year":"2009","unstructured":"Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, Inaba Y, Takahashi K (2009) Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66(2):176\u2013183. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2009.02.004","journal-title":"Lung Cancer"},{"issue":"3","key":"9984_CR21","first-page":"742","volume":"19","author":"T Zhang","year":"2014","unstructured":"Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN (2014) Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 19(3):742\u2013748","journal-title":"J BUON"},{"issue":"8","key":"9984_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1158\/0008-5472.CAN-16-0808","volume":"77","author":"M Wang","year":"2017","unstructured":"Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H (2017) Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway. Cancer Res 77(8):2018\u20132028. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0808","journal-title":"Cancer Res"},{"issue":"1","key":"9984_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2009.03.017","volume":"67","author":"L Zhang","year":"2010","unstructured":"Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X (2010) Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 67(1):114\u2013119. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2009.03.017","journal-title":"Lung Cancer"},{"issue":"1","key":"9984_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11670-011-0064-9","volume":"23","author":"Y Liang","year":"2011","unstructured":"Liang Y, Li H, Hu B, Chen X, Miao JB, Li T, You B, Chen QR, Fu YL, Wang Y, Hou SC (2011) Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer. Chin J Cancer Res 23(1):64\u201368. \n                    https:\/\/doi.org\/10.1007\/s11670-011-0064-9","journal-title":"Chin J Cancer Res"},{"key":"9984_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-9966-32-45","volume":"32","author":"Y Chen","year":"2013","unstructured":"Chen Y, Liu H, Wu W, Li Y, Li J (2013) Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res 32:45. \n                    https:\/\/doi.org\/10.1186\/1756-9966-32-45","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"9984_CR26","first-page":"295","volume":"37","author":"JC Han","year":"2015","unstructured":"Han JC, Xu F, Du J, Zhang YJ, Wei YJ, Li HB, Li XD (2015) Serum osteopontin levels correlate with clinical and pathological features in non-small cell lung cancer. Anal Quant Cytopathol Histpathol 37(5):295\u2013301","journal-title":"Anal Quant Cytopathol Histpathol"},{"issue":"8","key":"9984_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3109\/00365513.2011.621549","volume":"71","author":"F Karadag","year":"2011","unstructured":"Karadag F, Gulen ST, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, Cildag O (2011) Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest 71(8):690\u2013694. \n                    https:\/\/doi.org\/10.3109\/00365513.2011.621549","journal-title":"Scand J Clin Lab Invest"},{"key":"9984_CR28","doi-asserted-by":"publisher","first-page":"846142","DOI":"10.1155\/2014\/846142","volume":"2014","author":"Y Hao","year":"2014","unstructured":"Hao Y, Liu J, Wang P, Wang F, Yu Z, Li M, Chen S, Ning F (2014) OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC. Int J Genomics 2014:846142. \n                    https:\/\/doi.org\/10.1155\/2014\/846142","journal-title":"Int J Genomics"},{"key":"9984_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcdb.2016.08.032","volume":"64","author":"L Shi","year":"2017","unstructured":"Shi L, Wang X (2017) Role of osteopontin in lung cancer evolution and heterogeneity. Semin Cell Dev Biol 64:40\u201347. \n                    https:\/\/doi.org\/10.1016\/j.semcdb.2016.08.032","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"9984_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.12668","volume":"150","author":"R Singh","year":"2017","unstructured":"Singh R, Hui T, Matsui A, Allahem Z, Johnston CD, Ruiz-Torruella M, Rittling SR (2017) Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin. Immunology 150(1):74\u201386. \n                    https:\/\/doi.org\/10.1111\/imm.12668","journal-title":"Immunology"},{"issue":"1","key":"9984_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2567.2010.03335.x","volume":"132","author":"NA Atai","year":"2011","unstructured":"Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ, Sodek J (2011) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132(1):39\u201348. \n                    https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03335.x","journal-title":"Immunology"},{"issue":"8","key":"9984_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-017-1976-0","volume":"66","author":"EB Eruslanov","year":"2017","unstructured":"Eruslanov EB (2017) Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer. Cancer Immunol Immunother 66(8):997\u20131006. \n                    https:\/\/doi.org\/10.1007\/s00262-017-1976-0","journal-title":"Cancer Immunol Immunother"},{"key":"9984_CR33","doi-asserted-by":"publisher","first-page":"4049098","DOI":"10.1155\/2017\/4049098","volume":"2017","author":"LM Castello","year":"2017","unstructured":"Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A (2017) Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017:4049098. \n                    https:\/\/doi.org\/10.1155\/2017\/4049098","journal-title":"Mediators Inflamm"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-019-09984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-019-09984-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-019-09984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:50:56Z","timestamp":1596271856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-019-09984-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["9984"],"URL":"https:\/\/doi.org\/10.1007\/s10585-019-09984-z","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Francesco Grossi has consulting\/advisory relationship with and received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, and Pierre Fabre and has consulting\/advisory relationship with AstraZeneca and Roche. Carlo Genova received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb. Erika Rijavec received honoraria from Bristol-Myers Squibb (H). Paolo Spallarossa has consulting\/advisory relationship with Incyte, Teva, Bristol-Myers Squibb and received honoraria from Incyte, Teva and Servier. The other authors indicated no financial relationship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}